FOLFIRINOX de-escalation in advanced pancreatic cancer: a multicenter real-life study.
Fiche publication
Date publication
septembre 2020
Journal
The oncologist
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BORG Christophe, Dr VERNEREY Dewi, Dr VIENOT Angélique
Tous les auteurs :
Chevalier H, Vienot A, Lièvre A, Edeline J, El Hajbi F, Peugniez C, Vernerey D, Meurisse A, Hammel P, Neuzillet C, Borg C, Turpin A
Lien Pubmed
Résumé
Our study describes the feasibility and efficacy of a first-line FOLFIRINOX (5FU, folinic acid, irinotecan, and oxaliplatin) induction chemotherapy (CT) followed by de-escalation as a maintenance strategy for advanced pancreatic cancer (aPC).
Mots clés
FOLFIRINOX, advanced pancreatic cancer, maintenance treatment, quality of life, real-life study
Référence
Oncologist. 2020 Sep 4;: